Equities

Lupin Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Lupin Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,914.20
  • Today's Change-7.80 / -0.41%
  • Shares traded1.58m
  • 1 Year change+5.11%
  • Beta0.5197
Data delayed at least 15 minutes, as of Jul 09 2025 11:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.

  • Revenue in INR (TTM)227.08bn
  • Net income in INR32.82bn
  • Incorporated1983
  • Employees21.87k
  • Location
    Lupin Ltd3rd Floor,Kalpataru Inspire,, Off. Western ExpressMUMBAI 400055IndiaIND
  • Phone+91 2 266402323
  • Fax+91 2 266402051
  • Websitehttps://www.lupin.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LUPIN:NSI since
announced
Transaction
value
Eli Lilly & Co-HuminsulinDeal completed30 Dec 202430 Dec 2024Deal completed-14.16%--
Boehringer Ingelheim Gmbh-Gibtulio TrademarkAnnounced13 Dec 202413 Dec 2024Announced-9.37%--
Boehringer Ingelheim Gmbh-Gibtulio Met TrademarkAnnounced13 Dec 202413 Dec 2024Announced-9.37%--
Boehringer Ingelheim Gmbh-Ajaduo TrademarkAnnounced13 Dec 202413 Dec 2024Announced-9.37%--
Data delayed at least 15 minutes, as of Jul 09 2025 11:27 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Glenmark Pharmaceuticals Ltd133.22bn10.47bn516.57bn14.99k49.345.8433.693.8837.1037.10468.57313.600.87621.575.12--6.891.3311.251.9267.3261.047.861.821.059.010.218439.6212.774.60155.146.18-4.240.00
GlaxoSmithKline Pharmaceuticals Ltd37.49bn9.28bn552.38bn3.11k59.8128.3155.5614.7354.5154.51220.41115.190.97832.7614.5712,043,720.0024.2015.3043.8125.6662.9056.7024.7416.771.54845.380.0051137.078.563.0657.2353.14-31.0316.00
Alkem Laboratories Ltd129.65bn21.65bn574.02bn17.28k26.514.7922.314.43181.11181.111,084.231,002.370.77951.675.46--13.3212.1218.1217.5363.2560.2117.0914.692.0217.620.1025.452.349.2120.5913.9513.2212.47
Aurobindo Pharma Ltd317.24bn34.86bn666.59bn8.80k19.192.0412.992.1059.8159.81544.32562.210.66891.286.01--7.348.6210.2512.1358.9454.5110.9812.381.139.690.202--9.396.559.864.1511.98--
Abbott India Ltd64.09bn14.14bn725.88bn3.81k51.3217.1548.8411.33665.62665.623,016.081,992.141.154.6117.65--25.4622.4233.8330.4245.4444.7022.0718.832.76141.980.044455.919.589.3817.7518.9927.3134.73
Lupin Ltd227.08bn32.82bn877.85bn21.87k26.805.1019.613.8771.7271.72496.28376.800.85371.284.46--12.434.5318.597.1669.8760.8814.565.951.2614.130.239629.5613.488.1171.41--20.1114.87
Zydus Lifesciences Ltd232.42bn45.26bn989.33bn26.24k21.864.1317.894.2644.9844.98231.01238.050.69921.685.02--13.8810.9219.4616.3572.7364.1219.8616.731.452,391.720.108717.8118.9010.2717.9630.9213.6325.74
Mankind Pharma Ltd122.79bn19.95bn1.00tn19.54k49.257.0037.848.1749.3849.27303.42347.390.61831.9010.28--10.1514.9312.8019.3971.5168.5116.4117.700.86425.770.3688--18.9815.793.9014.0318.41--
Dr Reddy's Laboratories Ltd326.44bn56.55bn1.07tn26.94k18.933.1814.383.2767.8167.81391.46403.240.73951.483.8212,115,460.0012.9712.1517.5416.9469.4366.1817.5415.811.3726.740.121114.6916.5413.261.3822.8441.269.86
Torrent Pharmaceuticals Ltd115.16bn19.11bn1.12tn16.11k58.8314.8141.559.7656.4756.47340.25224.280.76651.156.217,149,743.0012.729.5419.2014.7275.9072.5616.6014.140.653211.600.296761.097.357.7215.3914.488.5130.36
Cipla Ltd275.48bn52.73bn1.20tn30.31k22.813.8519.134.3665.2465.24340.86386.240.78591.645.369,087,725.0015.0911.8917.8814.4967.5959.5519.2114.743.2297.100.013822.406.889.9727.9327.809.1434.08
Data as of Jul 09 2025. Currency figures normalised to Lupin Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

20.13%Per cent of shares held by top holders
HolderShares% Held
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 15 Jun 202515.46m3.39%
ICICI Prudential Asset Management Co. Ltd.as of 31 May 202514.04m3.07%
Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 202410.36m2.27%
The Vanguard Group, Inc.as of 02 Jul 20259.02m1.98%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 20258.19m1.79%
SBI Funds Management Ltd.as of 31 May 20257.72m1.69%
HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 20257.47m1.64%
Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 May 20257.17m1.57%
BlackRock Fund Advisorsas of 03 Jul 20256.24m1.37%
Axis Asset Management Co. Ltd.as of 31 May 20256.22m1.36%
More ▼
Data from 31 Mar 2025 - 04 Jul 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.